Werner Syndrome by Chen, Lishan & Oshima, Junko
© 2002 Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology • 2:2 (2002) 46–54 • PII. S1110724302201011 • http://jbb.hindawi.com
REVIEW ARTICLE
Werner Syndrome
Lishan Chen and Junko Oshima∗
Department of Pathology, Box 357470, HSB K-543, University of Washington, Seattle, WA 98195-7470, USA
Received 19 December 2001; accepted 4 January 2002
Werner syndrome is a premature aging disease caused by the mutation in the WRN gene. The cloning and characterization of the
WRN gene and its product allows investigators to study the disease and the human aging process at molecular level. This review
summarizes the recent progresses on various aspects of the WRN research including functional analysis of the protein, interactive
cloning, complexes formation, mouse models, and SNPs (single nucleotide polymorphisms). These in depth investigations have
greatly advanced our understanding of the disease and elucidated future research direction for Werner syndrome and the human
aging process.
INTRODUCTION
Until recently, Werner syndrome (WS) had been consid-
eredamodelofacceleratedaging.TheWRN genewasidenti-
ﬁed in 1996 [1], and was subsequently shown to act both as a
DNAhelicaseandasanexonuclease[2,3].Sincethen,cancer
researchers and those that study DNA metabolism have col-
laborated to further characterize WS and the function of the
WRN gene. The more we understand about the WRN gene,
the more we realize that WS is not merely involved in accel-
erated aging. WS certainly does not represent premature ag-
ing, in a sense that the characteristic aging phenotypes seen
in WS are considerably diﬀerent from those observed in nor-
mal elders. WS is now being more correctly recognized as a
condition in which the lack of WRN protein (WRNp) results
in an overall decline in the normal physiological functions
of various organs, including those most frequently used to
estimate the chronological age, such as skin and hair.
Since the identiﬁcation of the WRN gene ﬁve years ago,
various in vitro biochemicalstudies of WRNp have answered
many of our initial questions regarding the helicase and ex-
onuclease functions of this enzyme. Considerably more time
will be required to answer the more diﬃcult questions con-
cerning the in vivo functions of WRN at the organism and
cellular levels. The lack of mouse models of WS that mimic
the human disorder currently limits our ability to carry out
such studies. In this review, the known in vitro functions
of WRNp and the cellular characteristics of WS cells will
be summarized. From this, the putative in vivo functions of
WRN will be extrapolated.
CLINICAL FEATURE OF WERNER SYNDROME
TheclinicalphenotypesofWScanbebestsummarizedas
onset of an aged-appearance and age-related common dis-
orders [4, 5, 6, 7]. Unlike people with Hutchinson-Gilford
progeria, WS patients usually develop normally until they
reach the second decade of life. Some patients may present
with ﬂat feet. Generally, the ﬁrst sign is a lack of the pubertal
growth spurt during the teen years. Patients frequently re-
call that they were of average height when they entered grade
school, but were the shortest ones in their class by the time
they graduated from high school. In their 20s and 30s, pa-
tients begin to manifest skin atrophy, loss of hair, and gray-
ing hair. Subcutaneous fat tends to deposit on the trunk, and
combined with osteoporosis of the limbs, patients exhibit a
stocky appearance. The other most common age-related dis-
orders seen in WS patients are bilateral cataracts and type II
diabetes mellitus. Penetrances are 98% for cataracts and 90%
for diabetes mellitus [7]. These numbers obviously depend
on the age of the patient when clinical reports are made,
and how rigorously patients were examined. Demographi-
cally, WS cases are most frequently reported in Japan. This
can be partly attributed to an awareness of the syndrome
among Japanese physicians, and the higher consanguinity
amongtheJapanesepopulationascomparedtotheUSpopu-
lation. The chronological order of the onset of these compli-
cationsissimilaramongCaucasianandJapaneseWSpatients
[6,7].TheInternationalRegistryofWernerSyndrome(Seat-
tle, Wash, USA) has documented more than 100 cases of WS.
New cases with a diagnosis conﬁrmed by genetic analysis are
mostly in patients over the ageof 30, probablydue to the lack
of prominent symptoms prior to the age of 20.
Two common causes of death among WS patients are
malignancy and myocardial infarction [6, 8]. Although these
are also two common causes of death in the general popu-
lation, unique characteristics are observed in WS patients.
An extensive review of malignancies has been carried out
in WS cases in Japan, where the prevalence of WRN muta-
tions is relatively high [9]. Strikingly, the ratio between can-
cers of epithelial origin and sarcomas of mesenchymal ori-
gins is 1:1 in WS patients, whereas this ratio is approximately2:2 (2002) Werner Syndrome 47
10:1inthegeneralpopulation.Apossibleexplanationforthe
high representation of mesenchymal tumors in WS patients
may be related to the mechanism by which telomere length is
maintained [10]. Review of the pathological studies of these
malignancies revealed unusual primary sites for cancers in
WS patients. For example, melanomas in WS patients are of
the acral lentigenous type in the mucosas, and are unrelated
to sun exposure [9]. The primary sites of osteosarcoma in
WS patients are more likely to be in the lower extremities,
whereas these are more common in the upper extremities in
the general population [11]. This variation may be related to
the threshold of WRNp required to maintain DNA stability
in each cell type within a given organ. Among WS patients,
the speciﬁc cell type in which cancer develops may diﬀer, de-
pending on the type of mutation in the WRN gene. Papil-
lary carcinoma has been associated with an N-terminal mu-
tation, whereas follicular carcinoma is more frequently ob-
served with a C-terminal mutation [5]. This ﬁnding clearly
contradicts our original assumption that all identiﬁed muta-
tions within WRN result in truncation of the nuclear local-
ization signal of WRNp, and thereby act as null mutations
(see Section “WRN mutations”). Further studies may reveal
additional correlation between speciﬁc genotypes and phe-
notypes.
Several other important diﬀerences have been noted be-
tween WS patients and normal elders. Atherosclerosis ex-
hibits unique characteristics in WS patients. Atherosclerotic
lesions are more extensive in arterioles as compared to non-
WS patients, who exhibit lesions primarily in major arteries.
Calciﬁcation of cardiac valves is also sometimes observed in
WS, possibly reﬂecting excessive cell death due to the con-
stant pressure of the blood ﬂow. Skin ulcers around the an-
kles and elbows that are more severe than those typically
seen in the progression of diabetes mellitus are not uncom-
mon in WS. Dementia of the Alzheimer type is relatively rare
[12] despite the fact that WRNp is expressed in the brain
[1]. Whereas in the general population, osteoporosis has a
more pronounced eﬀect on vertebrae, long bones, particu-
larly those of the lower limbs, tend to be more aﬀected by
osteoporosis in WS patients [13].
Werner syndrome was ﬁrst described by Dr Otto Werner
at Kiel University in his doctoral thesis at the turn of the 20th
century [14]. Two symptoms that drew his attention were bi-
lateral cataracts and scleoderma-like skin. The latter turned
out to provide insight into the interaction between WRNp
and the Ku complex (see Section “Telomere maintenance”),
the autoantigen that triggers scleroderma, an autoimmune
disorder.
WRN GENE PRODUCT
FunctionaldomainsofWRNgeneproduct
The WRN gene is comprised of 35 exons on the short
arm of chromosome 8, and encodes protein of 1432 amino
acids. It was identiﬁed in 1996 using a conventional posi-
tionalcloningapproach[1],andthemethodsthatwereavail-
able at that time [15]. Simple alignment in database searches
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Figure 1. Functional domains of the WRN protein. Arabic numbers in-
dicate amino acids of the WRN protein. The designated functions of the
exonuclease domains (I–III), the acidic repeat transcriptional activator re-
gions, helicase domains (I–VI), and nuclear localization signal have been
demonstrated in various biological assays. The roles of the RecQ C-terminal
conserved region and the helicase RNaseD C-terminal (HDRC) conserved
regions are based on the structural studies.
and more complicated structural studies showed four de-
ﬁned regions of WRNp. These include exonuclease domains
I,II,andIIIintheN-terminalregion[16,17];RecQ-typehe-
licase domains I, Ia, II, III, IV, V, and VI in the central region
[18]; a RecQ conserved motif immediately following the he-
licase motifs [19]; and a helicase ribonuclease D C-terminal
(HRDC) conserved motif in the C-terminal regions [19].
Biochemical studies conﬁrmed the helicase and exonu-
clease activity of WRNp in vitro [2, 3, 20]. The function
of the RecQ conserved motif has not been deﬁned. The
HRDC motif is thought to form a scaﬀold which interacts
with substrate DNA with relatively low aﬃnity, based on the
three-dimensional structure, which resembles the auxiliary
DNA-binding domains of bacterial DNA helicases [21]. Cell
biological studies identiﬁed two other functional domains.
One of these functions as a transcriptional activator within
a highly acidic region between the exonuclease and helicase
domains [22, 23]. The other functions as a nuclear localiza-
tionsignalintheextremeC-terminusofWRNp[24,25].The
relative locations of these structural domains are shown in
Figure 1.
WRNmutations
To date, at least 35 diﬀerent WRN mutations have been
reported from all over the world [1, 8, 26, 27, 28, 29] (see
Figure 2). The known mutations correspond to either stop
codons, insertions, or deletions that result in a frame shift,
or splicing donor or acceptor site mutations, which cause an
exontobeskipped,resultinginaframeshift.Allofthesemu-
tations result in truncation of the nuclear localization signal.
Unlike the BLM gene [30], no missense mutation has been
identiﬁed in WS. As we expand WS screening, this type of
mutation may be identiﬁed in future WS cases.
In addition to the loss of the nuclear localization signal
in WRN mutations, the mutant mRNAs, and the resulting
mutant proteins exhibit shorter half-lives than do the wild-
typemRNA,andWRNp[31,32].Mutantproductstruncated
N-terminal to the helicase regions were more labile than a
mutant protein truncated C-terminal to the helicase region.48 L. Chen and J. Oshima 2:2 (2002)
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Figure 2. WRN mutations in WS patients. The rectangular boxes indicate
the functional domains of the WRN protein (see Figure 1). Known WRN
mutations are grouped based upon the type of mutation, shown above and
u n d e r n e a t ht h eW R Np r o t e i nd i a gr a ma l o n gwi t hR e gi s t ryc o d e s .P a r e n t h e -
ses indicate the heterozygous mutations. R367Stp (∗∗) is the most common
mutation seen in Caucasian WS patients (approximately 25%) and the sec-
ond most common mutation in Japanese WS patients (approximately 18%)
[33]. Deletion of exon 26 (∗), which is due to a splice junction mutation, is
the most common mutation in Japanese WS patients (approximately 52%)
[33].
The biological signiﬁcance of low levels of mutant WRNp
in the cytosol is unknown. Depending on the speciﬁc mu-
tation, certain WRNp mutations can retain enzyme activity
or other functions. These proteins can modify DNA during
the mitotic phase or modify RNA during all phases of the
cell cycles. It is possible that various mutant forms of WRNp,
which may be retained in the cytosol, could contribute to the
slight diﬀerences in phenotype observed with various WRN
mutations. For example, thyroid cancer associated with the
two major WRN mutations diﬀers [5]. Papillary carcinoma
is associated with the N-terminal mutation, while follicular
carcinoma is seen more often with the C-terminal mutation.
WRNhelicaseactivity—effectofsingle-strandbinding
proteinsandsubstratespeciﬁcities
The helicase activity of WRNp is a RecQ-type helicase,
named after the prototypic Escherichia coli RecQ. A number
of laboratories have demonstrated that WRNp exhibits ATP-
dependent 3  → 5  helicase activity in an oligo-displacement
assay [2, 20, 34, 35, 36, 37]. One study showed that this activ-
ity was present in an immunoprecipitated sample of WRNp
[38]. WRNp appears to ﬁrst bind to the single-stranded por-
tionofthelongerstrandoftheDNAduplexandproceedsina
3  → 5  direction with respect to the longer strand [35]. This
3  → 5  movementcorrespondstothedirectionofproofread-
ing,asopposedtothedirectionofDNAsynthesis,whichpro-
ceeds from 5  → 3 .T h u s ,WRN has been proposed to play
a role in some aspects of DNA strand repair, although the
speciﬁc mechanisms involved are not known. WS cells are
hypersensitive to 4-nitroquinoline-1-oxide (4NQO) [39], al-
though WRNp does not have a higher binding aﬃnity for
DNA that has been damaged by 4NQO or by UV light [35].
The WRN helicase can also function to unwind DNA-RNA
duplexes [20].
The helicase activity of WRNp can be enhanced by the
presence of various single-strand binding proteins, such as
Escherichia coli SSB, the T4 gene 32 product or, more eﬃ-
ciently, human replication protein A (hRPA) [2, 20, 35, 36,
37, 40]. These single-strand binding proteins are believed to
facilitate WRN helicase activity by stabilizing single strand
structures and by preventing their re-annealing. Several in-
vestigators have demonstrated that WRNp and hRPA are
colocalized in Xenopus replication initiation complexes, and
in Hela cells arrested in S-phase with hydroxyurea [41, 42,
43]. Moreover, recombinant WRNp and puriﬁed hRPA have
been shown to co-immuno-precipitate [36]. hRPA might
playanadditionalrole,besidesstabilizingthesingle-stranded
DNA structure, in the WRN-catalyzed unwinding reaction,
which requires direct interaction with WRNp.
Several unusual substrates have been tested as potential
physiological targets for WRN helicase activity. WRN was
able to eﬃciently unwind a G4 quartet made by two hair-
pin loops (G’2 biomolecular tetraplex) of d(CGG)n [44]. In
this study, the G4 structure was generated under a high salt
concentration in vitro. Although its presence has not been
demonstratedinvivo,aG4quartetcanpotentiallybeformed
from two GC-rich regions of unwound single-stranded DNA
(or RNA) during replication, repair, recombination, or tran-
scription. Another interesting structure is a recombination
intermediate, or α structure. WRNp was able to promote
branch migration of a Holliday junction [42]. In fact, the
WRN helicase appeared to dissociate the α structure better
than a simple DNA duplex, as assessed by the length of the
migration. This structure can be formed both during recom-
bination and replication, such as break-induced DNA repli-
cation or repair of the stalled replication. The complex sec-
ondary structures described above were also substrates for
the BLM helicase in vitro. Thus, in vivo, WRNp may partici-
pate in the dissociation of these structures as well.
CharacteristicsandsigniﬁcanceofWRN
exonucleaseactivity
The 3  → 5  exonuclease activity of WRN has been
demonstrated by at least four independent laboratories [3,
40,45,46,47,48,49].Onegroupmeasured5  → 3  exonucle-
ase activity [34], although no laboratory has demonstrated
both 3  → 5  and 5  → 3  exonuclease activities in WRNp.
While exonuclease activity in the 3  → 5  direction does
not require adenine triphosphate (ATP), the enzyme activ-
ity is enhanced in the presence of ATP and is speciﬁc for the
3  recessed end of the duplex [3, 45, 46, 48]. The WRN ex-
onuclease utilizes the 3  end of the blunt end as well as the 3 
overhang end in presence of Ku70/80, the regulatory subunit
of DNA protein kinase (DNA-PK) [47, 49].Like its WRNhe-
licase activity, the exonuclease activity of WRN also digests
RNA-DNA heteroduplexes [48]. The exonuclease region of
the mouse WRNp showed an activity [48].
Double-stranded DNA substrates with multiple base-
pair mismatches within the duplex (termed bubbles)w e r e
moresusceptiblethanthosewithoutmismatchestodigestion
by the WRN exonuclease, but the presence of more than two
mismatches at the end of the substrate made them relatively
more resistant to digestion [46, 48]. Structures resembling2:2 (2002) Werner Syndrome 49
Holliday junction are also known to be more susceptible to
WRN exonuclease digestion than are simple DNA duplexes
[46] similar to human WRNp.
Relative substrate speciﬁcity suggests that, like the WRN
helicase, WRN exonuclease activity may be involved in re-
pairing DNA damage. The exonuclease and helicase activi-
ties of WRN are physically and functionally separable [3].
How exonuclease and helicase functions are speciﬁcally co-
ordinated during the DNA repair process remains unknown.
RegulationoftranscriptionalactivationbyWRN
Transcriptional activation of the WRN protein was orig-
inally suggested by ﬁndings in the yeast one-hybrid system
[1]. Subsequently, transactivation of the adenovirus major
late promoter was used as a reported plasmid to demonstrate
that WRN can mediate transcription activation [23]. This
deﬁcit was reversed by the addition of recombinant WRN
protein.Interestingly,amutantWRNproteindefectiveinhe-
licase activity (K577M) was unable to complement the re-
duced transactivation in WS nuclear lysates, indicating that
the transactivation function of WRN is coupled with its he-
licase/ATPase activities [23].
WRN PROTEIN COMPLEXES AND CELLULAR
FUNCTION OF WRN
Identiﬁcation of proteins that interact with WRN has
helped to shed light on the in vivo functions of WRNp. Some
laboratories have characterized the association of WRN with
speciﬁc candidate interacting proteins, while others have
screened cDNA libraries by the yeast two-hybrid system, iso-
lated the WRN complex from the cell extracts, or captured
the interacting proteins by binding to a WRNp aﬃnity col-
umn. Interestingly, each method identiﬁed diﬀerent sets of
WRN interacting proteins. Thus, WRN may associate with
diﬀerent protein complexes, depending on the status of DNA
metabolism during the time that the WRN protein was re-
cruited.
Cell biological studies also suggested that WRN has mul-
tiple functions. Two characteristics of WS cells that had been
well known, even before the WRN gene was identiﬁed, were
that these cells exhibit a shortened replicative lifespan and
genomic instability. More recently, studies of drug sensitivi-
ties and telomere metabolism led us to a better understand-
ing of the speciﬁc functions of WRNp. Interacting proteins
combined with cellular and subnuclear studies suggests that
WRN may be involved in a wide variety of DNA metabolic
processes.
DNAreplication
FFA-1 is a Xenopus ortholog of WRN,a n dw a so r i g i -
nally identiﬁed in the replication initiation complex of Xeno-
pus oocytes as being required for the formation of replica-
tion foci during DNA replication [41]. FFA-1 and the p70
subunit of RPA have also been co-immunoprecipitated from
lysates of Xenopus oocytes [43]. WRNp interacts with sev-
eral components of the DNA replication complex, including
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Figure 3. Proteins that interact with the WRN protein. Proteins known to
interact with WRNp at speciﬁc sites are shown schematically. The approxi-
mate regions of protein-protein interaction are indicated.
proliferatingcellnuclearantigen(PCNA)andtopoisomerase
I[50].TheN-terminalregionwithintheexonucleasedomain
of the WRNp, particularly the region including amino acids
168–246, strongly interacted with the C-terminal portion of
PCNA [50], as indicated in Figure 3. The N-terminal region
of recombinant WRNp appears to form mostly trimers, as
does PCNA, suggesting that the interaction between WRN
and PCNA involves quaternary structure [48].
DNApolymeraseδ
DNA polymerase δ (pol δ) participates in DNA replica-
tion and repair of DNA damage. This enzyme is also found
inthetelomerecomplex.Evidenceofphysicalinteractionbe-
tween WRN and pol δ initially came from a yeast two-hybrid
screen, in which the C-terminal region of WRNp was used as
the “bait” to capture the p50 subunit of pol δ, as shown in
Figure 3 [51]. Immunoprecipitation with an anti-p50 anti-
body resulted in a complex including p120, the catalytic sub-
unit of pol δ. In yeast, physical, and functional interaction
between WRN,a n dp o lδ requires the third subunit pol32p
[52].
Functional interaction of WRNp, and pol δ appears to be
unilateral. In a simple primer extension assay, the addition
of WRNp enhanced pol δ activity, whereas the addition of
polδ didnotstimulateexonulceaseorhelicaseactivities[52].
In contrast, WRNp did not stimulate either pol α-o rp o lε-
mediated DNA synthesis [52, 53]. The presence of WRNp
also enabled pol δ to transverse hairpin and G’2 bimolecular
tetraplex structures to complete DNA synthesis [53]. One of
the functions of WRNp may be to recruit pol δ to the com-
plex secondary DNA structure and to alleviate stalled DNA
synthesis [51, 53].
Homologousrecombination
One of the important biological functions of Ec o l i
RecQ is to suppress homologous recombination by dis-
rupting its intermediate structure [54]. The yeast homolog
of RecQ, Sgs1, is involved in both homologous recombi-
nation and in illegitimate recombination or nonhomolo-
gous end joining (NHEJ). Both the WRN and BLM heli-
cases are able to complement increased homologous recom-
bination and illegitimate recombination of an Sgs1 deletion50 L. Chen and J. Oshima 2:2 (2002)
mutant [55]. However, the cytogenetic characterization of
cellsfromBloompatientsshowsincreasedexchangesofsister
chromatids, whereas cells from WS patients exhibit translo-
cation mosaicism [56]. These ﬁndings suggest that the BLM
helicase may play a more prominent role in the suppression
of homologous recombination in vivo.
Repairofbreaksindouble-strandedDNA
DNA-PK is a protein complex including a protein ki-
nase catalytic subunit, DNA-PKcs, and a regulatory subunit,
Ku70/80 [57]. This protein complex is involved in the ini-
tial stages of NHEJ. WRNp has been shown to directly in-
teract with DNA-PKcs and Ku80 [47, 49, 57]. Association
of WRN with the Ku complex enhances its exonuclease ac-
tivity, but has no eﬀect on its helicase activity [49]. Upon
binding to Ku, WRN is able to degrade DNA from both the
5  recessed end (5  → 3  exonuclese activity), and from the
blunt end. This may explain why both 3  → 5  [3, 45, 58],
and 5  → 3  [34] exonuclease activities were observed in re-
combinant WRNp. The presence of exonuclease activity has
been speculated to be a necessary step for DNA-PK mediated
NHEJ prior to the polymerization, and ligation step medi-
ated by XRCC 4 and ligase IV [57]. In addition, the WRN
helicase may unwind broken ends of dsDNA in the search for
microhomology.
Telomeremaintenance
In a high quality immunoﬂuorescence study, Shiratori et
al[59]identiﬁednucleardotssuggestingthatWRNpislocal-
ized on telomeres. Johnson et al [10] demonstrated WRNp
co-localizes with various telomere components, including
TRFI and TRFII in six ALT cell lines. ALT cells lack telom-
erase activity, and the telomeres in these cells are presum-
ably maintained by recombination. Recombinant WRNp did
not unwind a G’2 tetraplex containing a telomere repeat se-
quence [44]. However, WRNp did appear to unwind up to
23kb of a PCR-generated telomere repeat sequence to ss-
DNA, and this process was stabilized by hRPA [60]. These
ﬁndings collectively suggest that WRNp plays an important
role in telomere maintenance.
During the serial passage of primary WS ﬁbroblasts,
telomeres became shortened more quickly, and telomeres in
cells that had stopped dividing were longer than those in
control ﬁbroblasts [61]. Telomeres of WS Lymphoblastoid
cell lines (LCLs) were unstable, and telomere length var-
ied more widely in LCLs from WS patients as compared
to those from normal subjects [62] .T h et e l o m e r el e n g t h
at which LCLs from WS patients went into crisis also var-
ied widely. It has been suggested that one way in which
WRNp may be involved in the ALT pathway is by regulat-
ingthenumberofextra-chromosomaltelomererepeats[63].
This may explain why the catalytic subunit of human telom-
erase (hTERT) is able to extend the replicative lifespan of
WS cells indeﬁnitely [64, 65, 66]. hTERT may be able to
circumvent the early halt of cell division in WS cells be-
cause the WRNp complex functions in pathways that are
distinct from hTERT-dependent telomere maintenance [63].
These ﬁndings provided signiﬁcant insight into the possible
mechanism of mesenchymal tumorigenesis in WS patients,
as ALT cell lines are frequently mensenchymal in origin
[10].
However, other important factors may also be involved
in regulation of telomere function. Hisama et al [67] showed
that both WRN and hTERT could complement 4NQO sen-
sitivity in SV40 transformed WS ﬁbroblasts. Introduction of
hTERT appeared to reprogram gene expression [66]. WRNp
may play an additional role in telomere maintenance, aside
from repair of damaged telomeres and immortalizing cells
that lack telomerase activity.
p53
As indicated in Figure 3, the C-terminal region of WRNp
interacts with the p53 tumor suppressor, as these proteins
can be co-immunoprecipitated [68, 69]. In the absence of
WRN, p53-mediated apoptosis is attenuated [68]. Overex-
pression of WRN enhances p53-dependent transcriptional
activation of p21Waf1 [69], and potentiates p53-mediated
apoptosis [69]. Synergistic actions of p53 and WRN have
been observed in mouse models of WS [70, 71].
SUMO-1
A yeast two-hybrid screen using mouse WRN as the
bait identiﬁed Ubc9 and SUMO-1 as WRN interacting pro-
teins[72].TheN-terminaldomain(aminoacids272–514)of
WRN interacts with both Ubc9 and SUMO-1.
MOUSE MODELS OF WERNER SYNDROME
There are currently three mouse models of Werner syn-
drome:
• WRN helicase domain deletion mice (WRN∆hel/
∆hel) [73],
• WRN truncation mutant mice (presumably null,
WRN−/−)[ 70], and
• transgenic mice expressing dominant negative WRN
(K577M-WRN) [74].
These various genetic mutations are depicted schematically
in Figure 4.
WRN deﬁcient mice carry a WRN gene with a frame
deletion of the helicase domains III and IV, as described by
Lebel and Leder [73]. These mice express a mutant WRN,
WRN∆hel/∆hel, which retains the exonuclease domains and
nuclear localization signal. Mouse ES cells showed hypersen-
sitivity to campthothecin, and mitomycin C and the growth
rateofembryonicﬁbroblastswasprogressivelyreducedasthe
cells were passaged. The mice exhibited a normal phenotype
at least until the age of 12 months [71].
Another mouse line expresses a mutant WRN protein
that is truncated in the middle of the helicase region, re-
sulting in mice that are functionally null (WRN−/−)[ 70].
This mutation resembles many of the mutations in WS2:2 (2002) Werner Syndrome 51
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Figure 4. Mouse models of Werner syndrome. Structures of human and mouse WRN proteins and the alterations in the WRN gene product in the three
mouse models of WS are shown.
patients. Embryonic ﬁbroblasts showed accelerated replica-
tive senescence, and this was enhanced in cells from mice on
aB L M + /− background. They did not show hypersensitivity
to campthothecin or 4NQO. Histopathological studies failed
to show any unusual lesions in these mice up to the age of 17
months [70].
Mice with either a deletion or a truncation in the WRN
helicase domain showed gross abnormalities when they were
c r o s s e dt om i c eo nap 5 3− /− background. WRN+/− mice
showed increased rates of mortality, as assessed by both me-
dian survival and maximum survival of the cohort of 48
WRN−/−;p 5 3−/− and 59 WRN+/−;p 5 3−/− mice [70]. Me-
dian lifespan of WRN−/−;p 5 3− /− mice was approximately
20% shorter than that of WRN+/−;p 5 3− /− mice. Inter-
estingly, WRN∆hel/∆hel; p53 − /− mice exhibited increased
numbers of tumors, and a larger variety of tumor types at
an earlier age, as compared to WRN+/+; p53 −/− mice [71].
BothstudiessuggestthatWRN andp53playasynergisticrole
in the maintenance of genomic stability.
The dominant negative WRN transgenic mouse line,
K577M-WRN, was developed in my laboratory [74]. These
mice express both a full length mutant (K577M) human
WRN and endogenous mouse WRN. The K577M muta-
tion abolishes the helicase and ATP-ase activity of WRN in
vitro, but not the exonuclease activity [2, 3]. Tail ﬁbrob-
lasts from K577M-WRN mice showed hypersensitivity to
4NQO and a reduced replicative lifespan, as determined by
clone size distribution [74]. These mice did not show any
histopathological abnormalities at least up to the age of 18
months.
To date, there is no animal model of WS that accurately
mimics the human disease. This is also true for some, if not
all,other mouse models ofRecQhelicase-deﬁcientdisorders.
This lack of success in reproducing human disease states in
rodents may be due to the diﬀerence between humans and
mice in maintaining genomic instability. Nevertheless, these
mouse models have greatly facilitated the characterization of
the functional interaction of WRNp with other proteins and
of the pathogenesis of WS phenotypes.
WRN POLYMERASE AND ITS ROLE OF WRN
IN “NORMAL” AGING
As y s t e m a t i cs e a r c ho ft h eWRN polymorphism across a
variety of ethnic groups identiﬁed 58 SNPs, single nucleotide
polymorphisms, in 35 exons, and ﬂanking introns. Of these,
15 are localized within the coding region and 11 of these re-
sult in alterations in amino acid sequence [75, 76]. A lim-
ited association study of the two known WRN SNPs with
relatively high heterogeneity suggested that WRN may be
involved in determining longevity, possibly by modulating
the risk of a variety of common age-related disorders, in-
cluding atherosclerosis. Statistically signiﬁcant associations
with longevity and atherosclerosis were observed for the
1074Leu/Phe mutation [77]. In addition, the 1367Cys/Arg
mutation was associated with myocardial infarction [78],
atherosclerosis [77, 79], and long-term hemodialysis [80].
These two polymorphic sites are in linkage. The functional
manifestations of these two SNPs, with regard to WRN func-
tion, are unknown. However, it is of interest to note that
1074Leu/Phe resides within the RecQ consensus domain and
1367Cys/Arg is four amino acids away from the nuclear lo-
calization signal. Interestingly, in 1367Cys/Arg, the beneﬁ-
cial allele, Arg, is a minor allele. This might be explained by
thepresenceoflinkagedisequilibriumbetween1074Leu/Phe
and 1367Cys/Arg in some populations [76, 77]. The rela-
tive contribution of WRN polymorphisms to the risk of age-
related disorders or longevity may not be nearly as high as
other major known genetic risk factors, for example, poly-
morphisms in ApoE [75]. However, these studies are begin-
ning to provide hints that WRN may indeed be involved in
the “normal” aging process in the general population.
SUMMARY
Following the initial biochemical characterization of the
helicase and exonuclease activities of WRNp, the identiﬁca-
tionofWRN-interactingproteinshasledtoavarietyofstud-
ies exploring various ways in which WRNp may be involved52 L. Chen and J. Oshima 2:2 (2002)
in DNA metabolism. These include DNA repair at the site
of stalled replication and NHEJ. WRN may also have a spe-
cial role in transcription by RNA polymerases I and II, as
well as in homologous recombination. Cell biological studies
raise an interesting question regarding the role of WRN in
telomere maintenance. If WRN is capable of all these func-
tions, how do cells regulate the functions of WRN at any
given time? How is the switching of these roles mediated?
How are the relationships with other RecQ helicases regu-
lated? Since symptoms of WS are relatively mild (not lethal),
WRN may have evolved for the “ﬁne tuning” of these var-
ious DNA metabolisms. If this hypothesis is true, what are
the driving forces for the origin of WRN? At the animal level,
how is WRN involved in the progression of “normal” aging
phenotypes? I look forward to learning the answers to these
and other important questions during the coming decades.
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